Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05260086
Other study ID # 01759
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 15, 2019
Est. completion date May 12, 2022

Study information

Verified date May 2022
Source University Medical Center Goettingen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators compare the primary and secondary outcome measures using accelerated intermittent theta burst stimulation (aiTBS, 20 sessions active and 20 sessions sham in a counterbalanced crossover design) to treat depressive symptoms with 2 parallel arms of intervention: personalized (stimulation position based on participants' brain networks) vs conventional (stimulation in F3 position of the 10-20 EEG cap) aiTBS.


Recruitment information / eligibility

Status Completed
Enrollment 92
Est. completion date May 12, 2022
Est. primary completion date May 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Men and women between the ages of 18 and 60 years - Diagnosis of major depressive disorder according to DSM 5 (F32.x according to ICD-10) or bipolar disorder (bipolar I or bipolar II) according to DSM 5 (F31.x according to ICD-10) and an acute depressive condition at the time of the initial examination in outpatient or inpatient treatment (e.g. Department of Psychiatry and Psychotherapy, UMG) - Availability of informed consent to participate in the study, including the examinations and interventions Exclusion Criteria: - Neurological diseases, current or previous - Other Axis I diagnoses that mimic the affective disorder, current or previous - Physical illnesses that could be related to the affective symptoms (so-called organic causes) - Illicit drug use in the past month - Substance dependence, current or previous - Physical illnesses which, depending on their type and severity, could interfere with the planned examinations, influence the parameters to be examined or endanger the test participant during the course of the examination - Medical contraindications against performing an MRT examination / rTMS application (such as metal parts in the body, e.g. implants, pacemakers, infusion pumps, metal splinters, etc.) - Pregnancy - Previously known cerebral-morphological abnormalities (e.g. tumor, lesion, etc.) - Evidence or history of epilepsy - Head trauma with a history of loss of consciousness - Unwillingness to be informed of incidental findings - Participation in an rTMS / EKT application within the last 8 weeks - Lack of the ability to provide informed consent

Study Design


Intervention

Device:
Neuronavigated aiTBS
Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)

Locations

Country Name City State
Germany Laboratory of Systems Neuroscience and Imaging in Psychiatry (SNIP-Lab Göttingen) Göttingen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Goettingen

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Montgomery-Åsberg Depression Rating Scale (MADRS scores in units of scale) Administer Rating Scale 6 weeks
Primary heart rate and its variability in RR slope and RMSSD values Potential marker of treatment response 4-6 weeks
Secondary Hamilton Rating Scale for Depression (HAMD-17 scores in units of scale) Administer Rating Scale 6 weeks
Secondary Beck Depression Inventory (BDI-2 scores in units of scale) Self Rating Scale 6 weeks
Secondary DMN decoupling / other networks in rho and z values Potential markers of treatment response 4-6 weeks
Secondary epi / genetic markers of neuroplasticity in ng Potential markers of treatment response 5-6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A